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Summary 1 
Background New-generation drug-eluting stents (DES) have been mostly investigated by means of 2 
head-to-head non-inferiority trials, which typically showed comparable efficacy and greater safety as 3 
compared with early-generation DES. Evidence related to new-generation DES versus bare-metal stents 4 
(BMS) is more limited, and there remain uncertainties on their comparative safety profile. 5 
Methods We performed an individual patient data (IPD) meta-analysis of randomized trials 6 
comparing new-generation DES with BMS among patients undergoing percutaneous coronary intervention. 7 
The protocol of the study was registered in PROSPERO (CRD42017060520). The primary outcome was the 8 
composite of cardiac death or myocardial infarction. Data were pooled in a one-stage random effects meta-9 
analysis and examined at maximum follow-up and with 1-year landmark. Risk estimates are reported as 10 
hazard ratio (HR) with 95% confidence intervals (95%CI). 11 
Findings We obtained IPD data from 20 randomized trials including a total of 26,616 patients, with 12 
3·2±1·8 years mean follow-up. The primary outcome occurred in fewer patients in the DES group than in the 13 
BMS group (HR 0·84, 95%CI 0·78 to 0·90, P<0·001) owing to lower risk of myocardial infarction (HR 0·79, 14 
95%CI 0·71 to 0·88, P<0·001) and weaker evidence for a possible cardiac mortality benefit (HR 0·89, 95%CI 15 
0·78 to 1·01, P=0·075). All-cause death was unaffected (HR with DES, 0·96, 95%CI 0·88 to 1·05, P=0·358), 16 
but DES reduced the risk of definite stent thrombosis (HR 0·63, 95%CI 0·50 to 0·80, P<0·001) and target-17 
vessel revascularization (HR 0·55, 95%CI 0·50 to 0·60, P<0·001). There was evidence for a time-dependent 18 
treatment effect, with DES being associated with lower risks of the primary outcome during the first year 19 
followed by a null effect in the subsequent years. 20 
Interpretation New-generation DES instead of BMS were associated with sustained reduction of 21 
cardiac death or myocardial infarction owing to lower event rates within the first year without offsetting effects 22 
thereafter.  23 
Key words: Drug-eluting stent – Bare metal stents –– Percutaneous coronary intervention –– Meta-analysis 24 
 25 
 4 
Introduction 1 
Percutaneous coronary intervention (PCI) for the treatment of obstructive coronary artery disease is the most 2 
commonly performed cardiovascular procedure and one of the most frequent interventions in medicine. By 3 
using antiproliferative agents, drug-eluting stents (DES) reduce restenosis by inhibiting neointimal 4 
hyperplasia and have marked an important milestone in the field of myocardial revascularization, allowing 5 
PCI to be adopted in an increasing number of patient and lesion subsets.1  6 
Early-generation DES, releasing sirolimus or paclitaxel were associated with similar risks of death and 7 
myocardial infarction (MI), but with an increased, albeit small, risk of stent thrombosis beyond 1 year after 8 
stent implantation as compared with bare-metal stents.2,3 Since then, new platforms for DES that are aimed 9 
at improving safety and efficacy have been developed. 10 
Contemporary DES reduce the risk of stent thrombosis as opposed to earlier iterations and retain greater 11 
efficacy than bare-metal stents (BMS) in limiting the risk of repeat revascularization.4 In addition, randomized 12 
evidence mainly derived from network meta-analyses suggests that new-generation DES might also 13 
decrease the risk of stent thrombosis compared with BMS.5,6 However, new-generation DES have been 14 
mostly investigated by means of head-to-head non-inferiority trials in comparison with early-generation DES 15 
and it remains unclear whether they improve other outcomes than stent thrombosis and repeat 16 
revascularization procedures as compared with BMS, which continue to be employed in a sizable proportion 17 
of patients worldwide.7  18 
 19 
Methods 20 
The protocol was developed according to the guidelines of the Preferred Reporting Items for a Systematic 21 
Review and Meta-analysis of Individual Participant Data (PRISMA-IPD) Development Group8 and was 22 
registered online in the PROSPERO international prospective register of systematic reviews 23 
(http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017060520). 24 
 25 
Search strategy and eligibility criteria 26 
We performed an IPD meta-analysis of randomized trials that compared new-generation DES versus BMS 27 
among patients with coronary artery disease undergoing PCI. We used a broad definition for new-generation 28 
DES that were considered as any DES subsequent to the Cypher sirolimus-eluting stent (Cordis, Miami 29 
Lakes, Florida, USA) and the Taxus paclitaxel-eluting stent (Boston Scientific, Natick, Massachusetts, USA). 30 
In order to qualify, trials had to use new-generation DES in at least 90% of patients randomized to the 31 
 5 
experimental arm. Two investigators (RP and AB) determined trial eligibility criteria and a third investigator 1 
(MV) was involved in case of disagreement. Randomized trials were identified by a systematic search in 2 
PubMed, EMBASE, and three websites (www.tctmd.com, www.escardio.org, www.cardiosource.com). 3 
Reference lists of retrieved articles were hand searched. There were no language restrictions. A search 4 
algorithm (last updated on December 19th, 2017) is provided in the web-appendix. 5 
 6 
Data collection and quality assessment 7 
We contacted the principal investigators of the eligible trials, requesting IPD to be provided in an anonymized 8 
electronic dataset (web appendix). Data for five randomized trials were already available from a previous 9 
study.9 Data were checked for completeness and consistency, and were compared with the results of the 10 
original publications. The principal investigators of the included trials were contacted in case of missing data 11 
or when queries emerged during the integrity checks. Once queries had been resolved, the clean data were 12 
uploaded to the main study dataset. Two investigators (RP, AB) independently assessed the quality of 13 
included trials using the Cochrane Collaboration’s tool for assessing risk of bias. Disagreements were 14 
resolved first by discussion and then by consulting a third author (MV) for arbitration. Each trial had been 15 
approved by its local medical ethics committee, and all patients had provided written informed consent. 16 
 17 
Outcomes 18 
The prespecified primary outcome in this meta-analysis was the composite of cardiac death or myocardial 19 
infarction. Secondary outcomes were all-cause death, cardiac death, MI, target-vessel revascularization 20 
(TVR), and definite stent thrombosis. Outcomes were analyzed at the longest available follow-up in the 21 
primary analysis, as well as at 5-year follow-up and with a 30-day and 1-year landmark.  22 
 23 
Data analysis 24 
Continuous variables were summarized by their means and standard deviation across all included patients. 25 
The two treatment groups were compared with ANOVA statistic stratified by trial. Categorical variables were 26 
summarized by the corresponding counts and percentages, and were compared with the Cochran-Mantel-27 
Haenszel statistic stratified by trial.  28 
All outcomes were analyzed using time-to-event analysis. We first summarized the data using unadjusted 29 
Kaplan-Meier estimates at the longest available follow-up. We then performed a series of IPD random-30 
effects meta-analyses. All analyses were performed according to the intention-to-treat principle and utilized 31 
 6 
IPD. For all analyses, the pooled risk estimates were expressed as hazard ratios (HRs) with 95% confidence 1 
intervals (CIs). For the primary analysis, we used a one-stage IPD meta-analysis model.10 In this approach, 2 
we synthesized IPD from all trials simultaneously while preserving the randomization of the original trials. In 3 
sensitivity analyses we used a two-stage approach and analyzed the data from each study independently, 4 
using a Cox-regression model and then combined the study-specific logarithms of the HR and the 5 
corresponding standard errors at the second stage, using the DerSimonian-Laird random effects model with 6 
Hartung-Knapp variance estimator.11 In a further analysis, we performed a one-stage fixed-effect analysis by 7 
using Cox-regression model stratified by trial. For the one-stage IPD meta-analysis we assessed the extend 8 
of heterogeneity by assessing the estimated value of τ, i.e. the standard deviation of random effects; for the 9 
two-stage IPD meta-analysis we also calculated visually inspected the forest plots and calculated the I2 10 
statistic.12 To account for τ in the uncertainty around the pooled risk estimates, we also calculated 95% 11 
prediction intervals for hazard ratios.13 The number needed to treat for benefit (NNTB) was derived from the 12 
inverse of the absolute risk reduction. We performed a landmark analysis by setting as a landmark at 1 year 13 
and derived the p value of the interaction for effect modification by period (web-appendix).14 14 
Possible sources of heterogeneity in treatment effect were explored by assessing the effect of prespecified 15 
variables on the primary outcome using a one-stage IPD meta-analysis model with treatment-covariate 16 
interactions.15 The model is described in the web-appendix. We fitted a separate model for each covariate. 17 
The prespecified variables were: age (analyzed as a continuous variable), gender, diabetes, clinical 18 
presentation at the time of PCI, overlapping stent, multivessel disease, number of implanted stents, PCI on 19 
the left anterior descending artery, mean stent diameter, use of glycoprotein IIb/IIIa receptor inhibitors, use of 20 
newer P2Y12 receptor inhibitors. In a sensitivity analysis we also fitted an IPD model that separated the 21 
within- and across-trial treatment-covariate interactions, so as to avoid ecological bias.15 22 
All P values we calculated were based on 2-sided tests. A P-value less than 0·05 was considered significant 23 
for all analyses. We used Stata Statistical Software, release 14 (StataCorp LP, College Station, Texas) and 24 
R version 3.2.1 for all statistical analyses. 25 
 26 
Additional analyses 27 
We conducted sensitivity analyses excluding patients who underwent PCI with implantation of early-28 
generation DES (115 patients had received the Cypher DES and 90 patients had received Taxus DES) and 29 
patients who received thick-struts BMS (defined as a strut thickness >100 µm). A landmark analysis with two 30 
timepoints (30 days and 365 days) was also performed in order to further appraise the differential 31 
 7 
contribution of very early stent failure events, mainly thrombotic in nature, as opposed to those occurring in 1 
between 30 days and 1 year, mostly related to an abnormal healing process leading to neointimal 2 
hyperplasia (web-appendix). 3 
 4 
Role of the funding source 5 
There was no industry involvement in the design, analysis or funding of this study. This study was funded by 6 
institutional support of the Department of Cardiology at Bern University Hospital, Bern, Switzerland, which 7 
had no role in the data analysis, interpretation, or writing of the report. The corresponding and first and third 8 
authors (MV, RP, and OE) had full access to the data and had final responsibility for the decision to submit 9 
for publication.10 
 8 
Results 1 
We screened 19,454 unique citations. Of these, 601 were judged potentially eligible during screening 2 
of titles and abstracts, and 20 deemed eligible after full text review (Figure 1). IPD were sought and obtained 3 
for all 20 studies, which, therefore, contributed to the IPD meta-analysis. The web-appendix describes trial 4 
characteristics, patient populations, and the definitions used for outcomes (Tables S1-S3). Overall, we 5 
obtained data for 26,616 participants; 14,070 (53%) randomized to DES and 12,546 (47%) randomized to 6 
BMS. Baseline clinical characteristics were largely balanced between the two study groups (Table 1). 7 
Slightly more males were allocated to DES and patients randomized to BMS tended to receive stents with 8 
larger diameters and shorter lengths. Supplementary Table S4 provides details on the risk of bias 9 
assessment. Overall, trials were judged at low risk of bias, although blinding of patients and performing 10 
physicians was done only in four trials. 11 
Most patients received thin-strut stents, which, however, were less frequently implanted among 12 
those assigned to DES than BMS (79·7% vs. 85·3%, p<0·001). In the DES group, the following devices were 13 
implanted in more than 90% of patients: everolimus-eluting stents (Xience in 4,064 or 28·9%, Promus in 14 
2,866 or 20·4%, and Synergy in 596 or 4·2%), zotarolimus-eluting stents (Endeavor in 1,932 or 13·7%, and 15 
Resolute in 475 or 3·4%), biolimus-eluting stents (Biofreedom in 1,221 or 8·7%, Nobori in 765 or 5·68%, and 16 
BioMatrix in 655 or 4·86%), and sirolimus-eluting stents (Ultimaster in 375 or 2·78%) (Table S5). Early-17 
generation DES were implanted in a small proportion of patients (1·4%). In the BMS group, the following 18 
devices were implanted in about 80% of patients: Driver in 3,076 or 24·5%, Vision in 2,742 or 21·9%, 19 
Gazelle in 1,793 or 14·3%, Integrity in 914 or 7·3%, Libertè in 778 or 6·2%, Pro-kinetic in 768 or 6·1%, 20 
Omega/Rebel in 604 or 4·8%. Duration of dual antiplatelet therapy was on average 50 days longer after DES 21 
than BMS (302±179 vs. 253±176 days, p<0·001). 22 
The maximum length of follow-up ranged from 1 to 6 years with a duration of follow-up of 2 years or 23 
more in 14 trials and up to, or more than, 5 years in 6 trials. The mean (±standard deviation) follow-up time 24 
was 3·2±1·8 years (median, 2·1; interquartile range, 1·9 to 4·9). Ten trials reported sponsorship to be 25 
independent from industry (Table S1).  26 
At longest available follow-up, the risk of the primary outcome of cardiac death or MI was 27 
significantly lower among patients randomized to DES than BMS (14·49% vs. 16·65%, respectively; HR 28 
0·84, 95%CI 0·78 to 0·90, P<0·001), yielding a number needed to treat for benefit (NNTB) in the range of 46 29 
(Table 2, Figure 2). We found evidence that DES were associated with a reduced risk of MI as compared 30 
with BMS (HR 0·79, 95%CI 0·71 to 0·88, P<0·001), whereas the effect of DES vs. BMS on cardiac fatality 31 
 9 
rates was weaker and did not reach conventional levels of statistical significance (HR 0·89, 95%CI 0·78 to 1 
1·01, p=0·075). We found no difference between DES and BMS in terms of all-cause death (HR 0·96, 2 
95%CI 0·88 to 1·05, P=0·358). As compared with BMS, patients assigned to DES had a reduced risk of 3 
definite stent thrombosis (HR 0·63, 95%CI 0·50 to 0·80, P<0·001) and TVR (HR 0·55, 95%CI 0·50 to 0·60, 4 
P<0·001). Risk estimates for primary and secondary outcomes at 5-year follow-up were consistent with 5 
those observed at time of longest follow-up (Table 2).  6 
Results of the landmark analysis are reported in Figure 3 and Kaplan-Meier curves during different 7 
time intervals are shown in the web-appendix (Figure S1). For the primary outcome, there was significant 8 
heterogeneity in the treatment effect of DES vs. BMS before and after 1 year (P-int<0·001). DES compared 9 
with BMS reduced the risk of cardiac death or MI during the first year after implantation (HR 0·74, 95%CI 10 
0·67 to 0·81), but not beyond 365 days (HR 1·04, 95%CI 0·92 to 1·18). During the first year after PCI, DES 11 
use was also associated with a reduced risk of cardiac death (HR 0·82, 95%CI 0·70 to 0·96) and MI (HR 12 
0·69, 95%CI 0·62 to 0·78) when separately appraised, with no detectable treatment effect beyond 1-year 13 
(HR 1·03, 95%CI 0·84 to 1·26; P-int=0·079 and HR 1·06, 95%CI 0·93 to 1·22; P-int <0·001, respectively). A 14 
similar pattern was found for other secondary outcomes, such as stent thrombosis and TVR. In a further 15 
analysis with two landmark points, DES remained associated to consistently lower risks of the primary 16 
outcome, MI, ST, and TVR between 0 and 30 days as well as between 31 and 365 days (Table S6). 17 
The effect of DES versus BMS on the rate of the primary outcome at longest available follow-up was 18 
consistent across subgroups, including age, gender, clinical presentation, number and size of implanted 19 
stents, with the only exception for the target-vessel location (P-int=0·010) (Figure 4). There was strong 20 
evidence that DES lowers the risk of cardiac death or MI among patients undergoing stent implantation in the 21 
left anterior descending artery (HR 0·76, 95%CI 0·68 to 0·85, P<0·001). There was weak evidence of an 22 
effect in patients undergoing treatment in other coronary vessels (HR 0·92, 95%CI 0·82 to 1·02, P=0·112). 23 
We did not find clinically important heterogeneity in all meta-analyses, although there was a 24 
moderate heterogeneity for MI at longest follow-up, resulting in non-significant prediction intervals (Figure 25 
S2). 26 
 27 
Sensitivity analyses 28 
The main results of the IPD meta-analysis remained entirely consistent at the two-stage random effects 29 
approach (Table S7, Figure S2-S4) and one-stage fixed effect approach (Table S8). Results for primary and 30 
secondary outcomes remained unchanged after excluding patients who were randomized to BMS and 31 
 10 
received thick-strut stents and after excluding patients who randomized to DES and received early-1 
generation devices (Tables S9-S10). In a sensitivity analysis, we fitted a model including both within- and 2 
across-studies interactions between treatment and target-vessel location. Results were similar (P-int =0·018) 3 
to the ones obtained by the model including only a within-studies interaction.     4 
 11 
Discussion 1 
Using the totality of available data from randomized trials comparing new-generation DES with BMS among 2 
26,616 participants undergoing PCI, our collaborative IPD meta-analysis provides strong evidence that DES 3 
reduce the risk of cardiac death or MI compared with BMS at a mean follow-up time of 3·2 years or up to 5 4 
years. This benefit was mainly due to a decreased risk of MI with DES and a non-significant reduction of 5 
cardiac death as compared with BMS. The use of DES was also associated with a significantly lower risk of 6 
stent thrombosis and TVR at longest available follow-up or at 5 years. 7 
 8 
Introduced in 2002, DES represented a paradigm shift in the treatment of patients undergoing PCI owing to a 9 
convincing reduction in the need for repeat revascularization compared with BMS. However, after initial use 10 
and evaluation in clinical trials, safety concerns were raised due to excess of very late (>1 year) thrombotic 11 
events with early-generation devices.  12 
The transition from early- to new-generation DES, which are vastly represented in this study (>98% of 13 
participants), entailed a broad range of refinements, including the use of lower antiproliferative drug loads, 14 
the omission of paclitaxel as antiproliferative agent, thinner metallic stent struts, and more biocompatible 15 
durable or biodegradable polymers as well as polymer-free stents. Nevertheless, a lingering controversy 16 
exists as to whether the introduction of new-generation DES impacts on more prognostically relevant 17 
endpoints, such as death or MI.  18 
In the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) trial, which 19 
included 1,498 patients with acute myocardial infarction, there was a significant reduction in the risk of all-20 
cause death with DES compared with BMS at 5-year follow-up.16 Although this observation was mainly 21 
related to a decrease in non-cardiac fatalities, it has been speculated that the prevention of stent thrombosis 22 
and repeat revascularization among patients randomized to DES might have led to less rehospitalization and 23 
other complications including infections and sepsis, which were the second major cause of non-cardiac 24 
death in the trial.16 Conversely, the larger Norwegian Coronary Stent Trial (NORSTENT), which included 25 
9,013 patients, did not find evidence of a benefit of DES in terms of all-cause as well as cardiac death or MI 26 
rates.17 Yet, there was a significant 36% risk reduction for definite stent thrombosis with DES as compared to 27 
BMS. Fueled by greater safety perceptions and lower costs, BMS continue to be implanted in 20% of 28 
contemporary PCI procedures involving patients aged 65 years or older.7 While the use of BMS is no longer 29 
recommended across several guidelines of the European Society of Cardiology,18 no such position is 30 
endorsed by ACC/AHA guidelines, which, however, were published in 2011.19 31 
 12 
Our IPD meta-analysis provides robust evidence that the use of DES reduced by 21% the hazard of MI 1 
compared with BMS. This finding is relevant as only two out of 20 trials have individually reported a 2 
difference in MI between DES and BMS.20,21 Interestingly, both of these studies recruited mainly20 or 3 
exclusively21 patients deemed at high bleeding risk and mandated 1-month duration of dual antiplatelet 4 
therapy irrespective of stent types. Hence, the argument that DES implantation lowers MI rates because of 5 
concomitant longer duration of dual antiplatelet therapy seems invalid. The decreased hazard of MI with DES 6 
is biologically plausible given the concurrent reductions in stent thrombosis and TVR. The clinical correlate of 7 
stent thrombosis is death or MI in more than 90% of cases22 and roughly one third of patients with in-stent 8 
restenosis requiring repeat revascularization in a target-vessel is admitted with acute coronary syndrome.23 9 
Furthermore, restenosis after coronary stenting has been associated with a higher risk of mortality in cohorts 10 
undergoing angiographic surveillance.24 Even elective and uncomplicated revascularization in the target-11 
vessel is associated with an increased risk of mortality, partly related to a higher risk of myocardial infarction 12 
following repeat revascularization procedures.25  13 
Yet, we did not find evidence that the use of DES affects all-cause mortality whereas cardiac fatalities were 14 
only marginally and not significantly lower with DES at longest available follow-up.  15 
In our IPD analysis, 2,027 fatal events were observed of which less than 50% (997 or 49·2%) were from 16 
cardiac causes. Consequently, the predominant mode of death in patients undergoing PCI, particularly 17 
during the long-term follow-up, was non-cardiac, which is unlikely to be prevented by the type of coronary 18 
stent. These findings align well with other registry data showing a pronounced temporal switch from 19 
predominantly cardiac to predominantly non-cardiac causes of death after PCI in the past two decades.26 20 
There was evidence for time-dependent treatment effects, with DES being associated with lower risks of 21 
cardiac death during the first year followed by a null effect in the subsequent years. While interaction testing 22 
provided only borderline significance, the time-dependent distribution of the treatment benefit observed for 23 
cardiac mortality was highly consistent with those observed for other safety endpoints, including MI or stent 24 
thrombosis and even TVR, which was numerically but not significantly reduced from the second year 25 
onwards with DES. Hence, it remains plausible that an early cardiac mortality benefit, likely arisen by MI, ST 26 
and even TVR risk mitigation by DES within the first year, diminishes over time due to non-stent related 27 
fatalities.  28 
The observation that beneficial effects of DES on safety endpoints, including MI and ST, accrued exclusively 29 
within the first year after treatment and consistently within 30 days or in between 30 days and 1 year with no 30 
signal of further incremental benefit or loss thereafter is remarkable and deserves attention. First, it suggests 31 
 13 
that contemporary DES technology is less prone to thrombotic events early (i.e. within 30 days) after stent 1 
implantation and confirms the lower risk of non-fatal ischemic events associated to lower intimal hyperplasia. 2 
Second, it provides reassuring evidence that the long-term (beyond 1 year) safety issues, in terms of 3 
increased MI and ST rates observed with early generation DES as compared to BMS, has been resolved. 4 
Third, it shows that contemporary DES technology outperforms the safety and efficacy profile of BMS within 5 
the first year after implantation, without further comparative improvements being visible in the subsequent 6 
years. Hence, while BMS should no longer be considered the gold standard for safety, the observation that 7 
the risks of death or MI beyond 1 year after implantation do not differ between current generation DES as 8 
compared to BMS carries relevant clinical and pathophysiological implications and suggests that the focus of 9 
future technology should target clinical outcome improvements not only within but also beyond 1-year after 10 
stent implantation. 11 
 12 
A further strength of this IPD meta-analysis was the opportunity to explore the treatment effect of DES vs. 13 
BMS across several subgroups. We did not find any evidence of interaction between the primary outcome 14 
(cardiac death or MI) and any patient or lesion characteristic, except for target-vessel location. The reduction 15 
of the primary outcome with DES over BMS was more evident among patients who underwent PCI of the left 16 
anterior descending artery as opposed to other locations. As the myocardial territory supplied by the left 17 
anterior descending artery is larger than other vessels (45-55% of the left ventricle), it is likely that this 18 
patient population derived a greater benefit from the prevention of restenosis and stent thrombosis with DES 19 
compared with BMS.  20 
 21 
The results of this study should be interpreted in view of several limitations. First, the study has limitations 22 
inherent in patient-level, pooled analyses reflecting the shortcomings of the original studies. Second, 23 
although 90% of patients received a limited number of DES with everolimus-eluting stents being implanted in 24 
more than 50% of cases, a mixture of DES was used in the experimental arm. Third, a minority of patients 25 
received early-generation DES that are associated with lower safety and efficacy than new-generation DES 26 
and are no longer used in clinical practice. However, after the exclusion of these patients, results remained 27 
unchanged. Fourth, although there was no signal of difference between DES and BMS beyond 1 year, the 28 
mean follow-up in our IPD analysis was about 3 years and therefore longer duration follow-up is needed to 29 
confirm the durability of the benefit observed here at a medium-term time point. Fifth, the effect of stent 30 
selection on the MI type could not be assessed, as many of the included studies failed to collect this 31 
 14 
information. Finally, we did not adjust or account for post-randomization covariates, such as actual duration 1 
of dual antiplatelet therapy, to avoid violating the principle of randomization. However, several trials are 2 
under way to address the efficacy and safety of abbreviated antiplatelet regimens after contemporary PCI.27 3 
 4 
In conclusion, our collaborative meta-analysis based on the totality of available randomized data showed that 5 
the use of new generation DES rather than BMS, is associated with a sustained reduction in the risk of 6 
cardiac death or myocardial infarction, with time-dependent treatment effects characterized by a lower risk of 7 
the composite endpoint accrued during the first year without an off-setting effect during the subsequent 8 
years.  9 
 10 
 15 
Research in context 1 
Evidence before this study 2 
We searched PubMed, EMBASE, and three websites (www.tctmd.com, www.escardio.org, 3 
www.cardiosource.com) up to December 19th, 2017, to identify randomized trials comparing new-generation 4 
drug-eluting stents (DES) with bare-metal stents (BMS) in patients undergoing percutaneous coronary 5 
intervention (PCI). We used search terms “stents”, “drug-eluting stents”, “percutaneous coronary 6 
intervention” and “random*”. Trials were included if patients underwent PCI with the use of new-generation 7 
DES in at least 90% of the population allocated to the experimental arm. Evidence to support the use of new-8 
generation DES for PCI is mainly based on trials showing the superiority of newer DES in comparison to 9 
earlier generation DES or the non-inferiority between different types of new-generation DES. In contrast, 10 
evidence related to head-to-head comparisons between new-generation DES and BMS is more fragmented 11 
and, so far, it remains unclear whether new-generation DES improve clinical outcomes, such as myocardial 12 
infarction or cardiac death, as opposed to BMS. Only two separate studies have observed a reduction in the 13 
risk of myocardial infarction in favor of new-generation DES compared with BMS. Yet, almost all trials 14 
included repeat revascularization procedures in their primary endpoint and therefore provided imprecise 15 
estimates for less common but more prognostically relevant adverse events, such as myocardial infarction or 16 
cardiac death. After electronic search, we found 20 trials eligible for the study for which we requested and 17 
obtained IPD.  18 
Added value of this study 19 
In this IPD meta-analysis of randomized trials, we found that new-generation DES reduced the risk of cardiac 20 
death or myocardial infarction as compared with BMS. There was also strong evidence for a reduction of 21 
myocardial infarction, stent thrombosis and target-vessel revascularization, whereas cardiac death was 22 
numerically lower with DES without reaching formal statistical significance after a mean follow-up of 3·2±1·8 23 
years. By further investigating the treatment effects across different time-periods, we found that new-24 
generation DES reduced adverse events including cardiac death within 1-year with no signal of further 25 
incremental benefit or loss thereafter. At pre-defined subgroup analysis, we identified a stronger reduction in 26 
cardiac death or myocardial infarction with DES instead of BMS for patients who received stents in the left 27 
anterior descending artery, with positive interaction testing.  28 
Implications of all the available evidence 29 
Our study provides evidence that the use of new-generation DES instead of BMS is associated to improved 30 
outcomes as compared with BMS with reductions in both efficacy and safety parameters. The benefit of DES 31 
 16 
accrues early (i.e. within 1 year) after PCI and is maintained over longer term follow-up. The meta-analysis 1 
provides strong evidence that BMS should no longer be considered the gold standard for safety and 2 
questions their use in current clinical practice. 3 
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FIGURES LEGEND 1 
 2 
Figure 1. PRISMA Flow Diagram for the Systematic Review. 3 
 4 
Figure 2. Kaplan-Meier curves at longest follow-up for cardiac death or myocardial infarction (Panel A), all-5 
cause death (Panel B), cardiac death (Panel C), myocardial infarction (Panel D), target-vessel 6 
revascularization (Panel D), and definite stent thrombosis (Panel E). Red lines represent bare-metal stents 7 
and blue lines represent drug-eluting stents. 8 
 9 
Figure 3. Landmark analysis. P values for interaction are between hazard ratios (HR) with 95% confidence 10 
intervals (95%CI) calculated from 0 to 365 days and after 365 days. 11 
 12 
Figure 4. Subgroup analysis and meta-regressions for the primary outcome. BMS: bare-metal stents. CAD: 13 
coronary artery disease.  ACS: acute coronary syndrome. BMS: bare-metal stents. CAD: coronary artery 14 
disease. DES: drug-eluting stents. LAD: left anterior descending artery. 7: PCI percutaneous coronary 15 
intervention.  16 
 17 
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Table 1. Baseline and procedural characteristics. 1 
          
  
Drug-eluting stents 
(N=14,070) 
Bare-metal stents 
(N=12,546)   
P-
value 
          
Age, years n = 14067, 65·7±12·3 n = 12541, 66·3±12·4   0·458 
Male n = 14069, 10542 (74·9%) n = 12543, 9269 (73·9%)   0·067 
Smokers n = 13654, 4277 (31·3%) n = 12149, 3809 (31·4%)   0·092 
Hypertension n = 14029, 8259 (58·9%) n = 12500, 7324 (58·6%)   0·156 
Hyperlipidemia n = 13731, 7904 (57·6%) n = 12208, 6974 (57·1%)   0·208 
Diabetes n = 14046, 2740 (19·5%) n = 12525, 2344 (18·7%)   0·069 
Insulin-treated n = 2677, 446 (16·7%) n = 2323, 378 (16·3%)   0·426 
Previous MI n = 14025, 2143 (15·3%) n = 12505, 2007 (16·0%)   0·548 
Previous PCI n = 9950, 1901 (19·1%) n = 8507, 1806 (21·2%)   0·074 
Previous CABG n = 14060, 905 (6·4%) n = 12541, 1004 (8·0%)   0·605 
Indication to PCI         
Stable CAD n = 13927, 4047 (29·1%) n = 12408, 3644 (29·4%)   0·907 
Unstable angina n = 14012, 1959 (14·0%) n = 12478, 1871 (15·0%)   0·956 
Non-ST-elevation MI n = 13975, 3479 (24·9%) n = 12462, 3164 (25·4%)   0·636 
ST-elevation MI n = 13922, 4105 (29·5%) n = 12406, 3427 (27·6%)   0·522 
Gp IIb/IIIa receptor inhibitors n = 12344, 2781 (22·5%) n = 11020, 2378 (21·6%)   0·420 
Multivessel disease n = 13517, 5837 (43·2%) n = 11993, 4968 (41·4%)   0·239 
Number of implanted stents n = 14039, 1·6±1·0 n = 12507, 1·6±1·0   0·391 
Total stent length, mm n = 13956, 28·4±19·5 n = 12424, 26·9±18·2   <0·001 
Mean stent diameter, mm n = 13956, 3·3±0·5 n = 12421, 3·3±0·6   <0·001 
Overlapping stent n = 13403, 2395 (17·9%) n = 11877, 2152 (18·1%)   0·201 
Number of stented segments n = 14052, n = 12524,   0·088 
0 5 (0·0%) 5 (0·0%)     
1 10297 (73·3%) 9231 (73·7%)     
2 2758 (19·6%) 2480 (19·8%)     
3 751 (5·3%) 608 (4·9%)     
4 188 (1·3%) 141 (1·1%)     
5 40 (0·3%) 52 (0·4%)     
6 10 (0·1%) 6 (0·0%)     
7 3 (0·0%) 1 (0·0%)     
Target-vessel location         
Left main artery n = 13968, 1022 (7·3%) n = 12463, 591 (4·7%)   0·499 
Left anterior descending artery n = 13968, 6476 (46·4%) n = 12463, 5805 (46·6%)   0·859 
Left circumflex artery n = 13968, 4047 (29·0%) n = 12463, 3433 (27·5%)   0·51 
Right coronary artery n = 13968, 5260 (37·7%) n = 12462, 4674 (37·5%)   0·279 
Thin-strut stent (<100 μm) n = 14046, 11198 (79·7%) n = 12526, 10681 (85·3%)   <0·001 
Type of P2Y12 receptor inhibitor n = 12123, n = 10814,   0·919 
None 1 (0·0%) 3 (0·0%)     
 25 
Clopidogrel 10726 (84·8%) 10217 (90·0%)     
Ticagrelor 89 (0·7%) 63 (0·6%)     
Prasugrel 1837 (14·5%) 1069 (9·4%)     
Duration of DAPT, days n = 12200, 291·7±180·4 n = 10805, 244·2±175·9   <0·001 
          
All data are shown at patient-level. CABG: coronary artery bypass grafting; CAD: coronary artery disease; 
DAPT: dual antiplatelet therapy; Gp: glycoprotein·; MI: myocardial infarction. 
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Table 2· Results of one-stage meta-analysis. 1 
  
Drug-eluting stents 
(N=14,070) 
Bare-metal stents 
(N=12,546)   HR (95%CI) P-value τ 
At longest available follow-up             
Cardiac death or MI 1371 (14·49) 1472 (16·65)   0·84 (0·78 to 0·90) <0·001 0·003 
All-cause death 1031 (10·97) 996 (11·98)   0·96 (0·88 to 1·05) 0·358 0·004 
Cardiac death 494 (4·76) 503 (5·75)   0·89 (0·78 to 1·01) 0·075 0·003 
Myocardial infarction 1020 (11·65) 1124 (13·58)   0·79 (0·71 to 0·88) <0·001 0·070 
Target-vessel revascularization 920 (9·56) 1448 (14·95)   0·55 (0·50 to 0·60) <0·001 0·003 
Definite stent thrombosis 125 (1·20) 173 (1·70)   0·63 (0·50 to 0·80) <0·001 0·008 
At 5-year follow-up             
Cardiac death or MI 1345 (12·48) 1446 (14·16)   0·83 (0·78 to 0·90) <0·001 0·003 
All-cause death 1013 (9·82) 974 (10·44)   0·95 (0·88 to 1·05) 0·400 0·004 
Cardiac death 490 (4·55) 492 (4·84)   0·90 (0·79 to 1·03) 0·116 0·003 
Myocardial infarction 994 (9·56) 1099 (11·04)   0·78 (0·72 to 0·88) <0·001 0·056 
Target-vessel revascularization 904 (8·38) 1436 (13·40)   0·54 (0·50 to 0·59) <0·001 0·003 
Definite stent thrombosis 123 (1·09) 171 (1·58)   0·63 (0·50 to 0·80) <0·001 0·008 
At 1-year follow-up             
Cardiac death or MI 829 (5·95) 989 (7·96)   0·74 (0·67 to 0·81) <0·001 0·003 
All-cause death 499 (3·58) 495 (3·98)   0·94 (0·81 to 1·04) 0·197 0·003 
Cardiac death 301 (2·20) 331 (2·72)   0·82 (0·70 to 0·96) 0·016 0·003 
Myocardial infarction 591 (4·25) 746 (6·03)   0·69 (0·62 to 0·78) <0·001 0·070 
Target-vessel revascularization 547 (3·98) 1073 (8·77)   0·43 (0·39 to 0·48) <0·001 0·015 
Definite stent thrombosis 83 (0·60) 137 (1·11)   0·52 (0·40 to 0·69) <0·001 0·008 
              
BMS: bare-metal stents. DES: drug-eluting stents. MI: myocardial infarction.2 
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Figure 1. PRISMA Flow Diagram for the Systematic Review. 
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Figure 2. Kaplan-Meier curves at longest follow-up. 
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Figure 3. Landmark analysis.  
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Figure 4. Subgroup analysis and meta-regressions for the primary outcome. 
 
 
